25 genes were enriched in the MAPK pathway in our dataset, 21 of which were concentrated in primary and recurrent/metastatic tumors with MYCN amplification (12 of 16 cases; Figure 4 and Table 4). Here, MYCN is linked to metastatic neoplasm.